Improve Research Reproducibility A Bio-protocol resource
Concise Method
tooltip

Study design and settings

ML Moqi Liu
XJ Xueqiao Jiao
RL Rui Li
JL Jialu Li
LW Lu Wang
LW Liyan Wang
YW Yishu Wang
CL Chunmei Lv
DH Dan Huang
RW Ran Wei
LW Liming Wang
XJ Xunming Ji
XG Xiuhai Guo
ask Ask a question
Favorite

This is a single-center, prospective, randomized, open-label, blinded endpoint (PROBE) study. Participants were randomly assigned to five groups with different interventions: Acetazolamide group, Regular RIPC Training (Ripc) group, Rapid RIPC Training (Rapid-Ripc) group, Acetazolamide plus Rapid RIPC Training (Combined) group, and Control group. After the interventions, participants were exposed to a normobaric hypoxic chamber for 6 h (12% oxygen/88% nitrogen, approximately equivalent to an altitude of 4000 m after adjusting the difference between the actual altitude and the stimulated altitude in a normobaric hypoxic chamber [19]). The primary and secondary outcomes were assessed at baseline, before and after the 6 h of hypoxic exposure. We conducted the study in five rounds due to the large number of participants. Each round lasted for 1 week with 50 participants, with an overall study lasting from Dec. 2021 to Aug. 2022.

Copyright and License information: The Author(s) ©2023
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A